Since 2013, the Japanese Society for Vascular Surgery has started the project of nationwide registration and tracking database for patients with critical limb ischemia (CLI) who are treated by vascular surgeons. The purpose of this project is to clarify the current status of the medical practice for the patients with CLI to contribute to the improvement of the quality of medical care. This database, called JAPAN Critical Limb Ischemia Database (JCLIMB), is created on the National Clinical Database (NCD) and collects data of patients background, therapeutic measures, early results, and long term prognosis as long as five years after the initial treatment. The limbs managed conservatively are also registered in JCLIMB, together with those treated by surgery and/or EVT. In 2016, 1,092 CLI limbs (male 755 limbs: 70%) were registered by 91 facilities. ASO has accounted for 98% of the pathogenesis of these limbs. In this manuscript, the background data, the early prognosis, and 6-months prognosis of the registered limbs are reported. (This is a translation of Jpn J Vasc Surg 2019; 28: 1-27.)
Introduction
Recently, an increasing number of patients with critical limb ischemia (CLI) are undergoing medical care at clinical practice sites. Improving the outcome of treatment for these patients is an important and urgent issue. Since 2013, the Japanese Society for Vascular Surgery (JSVS) has initiated a nationwide CLI registration and tracking database project to obtain CLI epidemiological data that can be shared among the medical staff. The background of CLI limbs, contents of treatment, early outcome, and long-term outcome until five years after surgery, including non-surgical limbs, are registered in this database. The database was named JAPAN Critical Limb Ischemia Database (JCLIMB) and established on the National Clinical Database (NCD). The JCLIMB project s primary objective is to clarify the current status of CLI treatment performed by vascular surgeons in Japan and inform physicians at practice sites, thus improving the quality of medical care. The initial registration data, and their tracking data one month after registration in 2013-2015, have already been published. [1] [2] [3] [4] [5] [6] This article reports the basic data registered in 2016.
JCLIMB
Registration details, including the definition of CLI, have already been described in the 2013 annual report 1) . CLI to be registered was defined according to TASC II 7) : chronic ischemic rest pain, ulcers, or gangrene attributable to objectively proven arterial occlusive disease. CLI diagnosis should be confirmed by ankle pressure (AP) below 50 mmHg or by toe pressure (TP) below 30 mmHg in limbs with rest pain, and done by AP below 70 mmHg or by TP below 50 mmHg in limbs with ulcer or gangrene.
The same limb can be registered in JCLIMB only once within a five-year tracking period. When the registered limb is treated at different times or at different institutions, such data should be added only to the tracking items of each limb in JCLIMB, avoiding registration overlap. However, details of the procedure are registered each time in NCD apart from the registration in JCLIMB. On the other hand, the patient with bilateral CLI can be registered twice for each limb. Based on NCD regulations, fixing JCLIMB data is done as follows:
Initial registration data: Early April in the following year, Tracking data early after treatment (one month)/six months after treatment: End of December in the following year, Tracking data one year after treatment: End of December after two years. Tracking data two years after treatment: End of Decem-JSVS JCLIMB Committee, NCD JCLIMB Analytical Team ber after three years Tracking data three years after treatment: End of December after four years Tracking data four years after treatment: End of December after five years Tracking data five years after treatment: End of December after six years As a general rule, the timing of tracking data registration is accepted within a ±2-month range until 12 months after treatment, and within a ±3-month range thereafter. Although the day for tracking data fixing is specified, it is made flexible because, in some limbs, follow-up data might be revealed later.
It is very difficult to require facilities participating in NCD to register CLI data since a great number of registration items in JCLIMB would put too much burden on them. Thus, facilities wishing to participate were recruited. In total, 91 facilities, which registered CLI limbs in 2016 at the time of compiling in December 2016, are listed in the appendix.
Since JCLIMB is positioned as a registry study on NCD, patient consent to participate in the study, and the ethical review of the study at the time of participation in NCD were adopted.
Comments on the Aggregated Data in 2016
The initial registration data in 2016 were fixed in early April 2017, and the tracking data early after treatment (one month) were fixed on December 31, 2017. At that time, 1,092 limbs, those of 755 males (70%) and 337 females (30%), were registered in 91 facilities. All data and extracted data on arteriosclerosis obliterans (ASO) were collected according to the registered items. Since ASO accounted for 98% of all limbs, the overall and ASO data showed similar tendencies. In the comments, ASO data were presented in parentheses. In addition, because the Society for Vascular Surgery (SVS) s WIfI classification was reported in 2014 (Tables 1-1-1 to 1-1-3), 8) JCLIMB made several changes and additions to the registered items, making the WIfI classification possible since 2015 (Tables 1-2-1 to 1-2-3). The total figure was not always consistent, mostly due to missing values, and an explanation for each inconsistency was added.
(1) Pretreatment patients background
Pretreatment patients background is shown in Tables 2-1 to 2-6. Good blood pressure control was defined as below 140/90 mmHg, without diabetes and renal failure, or below 130/80 mmHg with these diseases. Diabetes control was considered good when hemoglobin A1c was below 7.0% (national glycohemoglobin standardization program [NGSP] value). Dyslipidemia control was considered good when low-density lipoprotein was below 100 and 80 mg/dL in the absence and presence of other arteriosclerotic diseases, respectively. The presence of heart failure was judged clinically. The patient was regarded as having heart failure based on a past history of admission due to heart failure, clinical symptoms of heart failure, a diagnosis of heart failure was confirmed by echocardiography, or reduced cardiac function on echocardiography even with no clinical heart failure symptoms. Renal dysfunction was graded following the new chronic kidney disease severity classification of the Clinical Practice Guidebook for Diagnosis and Treatment of Chronic Kidney Disease 2012 9) : Renal dysfunction was absent when the estimated glomerular filtration rate (eGFR) (mL/min/1.73 m 2 ) was 60 or higher, and it was graded as G3a, G3b, G4, and G5 when eGFR was 45-59, 30-44, 15-29, and below 15, respectively. eGFR below 15 in hemodialysis patients was graded as G5D.
The causes of the arterial occlusion of the limb were ASO in 1,070 (98%) limbs, thromboangitis obliterans (TAO) in 10, vasculitis (Takayasu s arteritis, collagen disease, Behçet s disease, and fibromuscular dysplasia excluding TAO) in nine, and others in three. Patients comorbidities consisted of diabetes in 66% (67%) of the limbs, hypertension in 76% (77%), dyslipidemia in 39% (39%), ischemic heart disease in 41% (42%), cerebrovascular disease in 21% (22%), dialysis for renal failure in 43% (44%), past medical history of malignant neoplasm or that being treated in 9% (9%), and arterial occlusive lesions in the contralateral limb in 80% (80%).
(2) Conditions of limb ischemia
Limb ischemia pretreatment conditions are shown in Tables 3-1 to 3-6. Regarding the walking function (Taylor s classification), 10) patients who could walk outdoors or indoors independently, including with a cane, were regarded as ambulatory, and those unable to walk but able to stand on their own legs during transfer from the bed to a wheel chair were designated as ambulatory/homebound.
Regarding the state of local tissue defect (University of Texas classification), 11) the most severe lesion, the main treatment target, was evaluated. Skin perfusion pressure (SPP) was measured on the foot (base of the toe, dorsum of the foot, or sole) and a lower value was adopted. To perform WIfI classification, the sites of ulcer and gangrene were registered separately. Although SPP is widely used as an objective index for evaluating ischemia in Japan, ischemic grading criteria using SPP is not shown in WIfI classification, in which TP is given top priority. Therefore, in JCLIMB, the SPP value was converted to TP using the conversion equation TP=0.6853 SPP+14.48 from the correlation data of SPP and TP reported in Japan, 12) and applied for WIfI ischemic grading ( Table 1-2-2) .
The lesion was considered infected when it showed two or more of the following findings: local swelling or induration, erythema >0.5 cm around the ulcer, local tenderness or pain, local warmth, and purulent discharge (thick, opaque to white, or sanguineous secretion). In addition, local infections involving only the skin and the subcutaneous tissue, and those involving structures deeper than the skin and subcutaneous tissues, were registered separately. Local infections involving only the skin and the subcutaneous tissue were differentiated based on the size of the erythema around the ulcer, ≦2 or >2 cm.
Systemic inflammatory response syndrome (SIRS), indicating systemic infection, was manifested by two or more of the following signs: temperature >38°C or <36°C, heart rate >90 beats/min, respiratory rate >20 breaths/min or PaCO 2 <32 mmHg, white blood cell count >12,000 or <4,000 cu/mm or 10% immature (band)
forms. The arteries in the ankle joint region were classified as foot arteries.
Pretreatment, 58% (58%) of the patients were ambulatory, 20% (20%) were ambulatory/homebound, and 22% (22%) were non-ambulatory. On the Rutherford classification (R), 13) limbs with categories R4, R5, and R6 accounted for 22% (22%), 65% (64%), and 14% (14%) of the limbs, respectively. The median ankle brachial index (ABI), the toe brachial index (TBI), and the SPP of the measured limbs were 0.58 (0.58), 0.32 (0.32), and 23 mmHg (24 mmHg), respectively. The occlusive legion was located in the aortoiliac artery in 22% (22%) of the limbs, in the femoropopliteal artery in 67% (68%) of the limbs, and in the crural or foot artery in 60% (60%) of the limbs. The occlusion of multiple lesions was observed in the aortoiliac artery and the femoropopliteal artery in 14% (15%) of limbs, in the aortoiliac artery and the crural or foot artery in 6% (7%), in the femoropopliteal artery and the crural or foot artery in 34% (35%), and in the aortoiliac artery and the femoropopliteal artery and the crural or foot artery in 6% (6%).
We were able to apply the WIfI classification with sufficient data to 865 limbs (848 limbs). On the WIfI classification, limbs with the stages 1, 2, 3, and 4 accounted for 14% (14%), 25% (25%), 23% (23%), and 37% (37%) of the limbs, respectively.
The problems and considerations on these spreadsheets are described below. In Table 3 -3, the total number of limbs in TASC II classification differed compared to the number in each column of the site of occlusion. In the aortoiliac lesion, a decreased number of that in TASC II classification may have been due to input omission. In the femoropopliteal lesion, an increased number of that in TASC II may have been due to including the crural lesions.
In Table 3 1-2 ). There should be no limb with Ischemic grade 0 since CLI registered in JCLIMB is defined according to TASC II. There is a possibility that the limbs clinically judged to be CLI were registered irrespective of the objective ischemic index, although details are unknown.
In Table 3 -6, there were 17 limbs (17 limbs) in which infection was confirmed in R4 limbs, despite the absence of a local wound by definition of R4. This may occur because tissue loss is not always requisite for fI grade.
In Table 3 -6, because ischemic grade data were registered in only 865 limbs (848 limbs) among 1,092 limbs (1,070 limbs), WIfI classification could be implemented for these 865 limbs (848 limbs). When rechecking the remaining 227 limbs (222 limbs), the data on TBI, SPP, or ABI in these limbs were registered as unmeasurable or unmeasured. The limbs clinically judged to be CLI could be registered without their objective ischemic index.
(3) Treatment
Tables 4-1 to 4-6 show the CLI treatment data. Revascularizations of the affected limbs were performed in 94% (94%) of the registered limbs, and primary major amputations were performed in 2.5% (2.5%) of the registered limbs. Among the surgical reconstruction procedures, distal bypass, a bypass to the crural or foot artery, accounted for 46% (45%). Endovascular treatment (EVT), including EVT alone and hybrid treatment with surgical reconstruction, accounted for 49% (49%) of the total revascularization procedures. EVT applied to the crural or foot artery accounted for 37% (37%) of the total EVT.
The problems and considerations on these spreadsheets are described below. Table 4 -1, the sum of the number of cells in treatment is larger than the number of registered limbs 1,092 (1,070) because more than one treatment method can be selected. The limbs undergoing pharmacological therapy alone accounted for 4.8% (4.7%). Table  4 -3, in the column of vein usage, described how the autologous veins were used when they were selected as vascular conduits. The sum of the number in the column with vein usage; in-situ, non-reversed, reversed, and spliced is larger than the sum of the number in the column of vein in vascular prosthesis. It could be because of JSVS JCLIMB Committee, NCD JCLIMB Analytical Team selecting multiple vein usage for arterial reconstruction in a limb since more than one vein usage can be selected. Two veins were used in eight limbs and three veins were used in one limb. Vascular prosthesis (−) included an endarterectomy without a patch angioplasty. Table 4 -4 shows the sum of the number of proximal anastomosis does not equal the sum of the number of distal anastomosis. This was because multiple veins in a limb were used. Two limbs had two proximal anastomoses (common femoral artery and crural artery) and one distal anastomosis (crural artery), which may be a sequential bypass, and one limb with one proximal anastomosis and two distal anastomoses was probably a duplicated bypass. Table 4 -6 summarizes the vascular grafts used for the infrainguinal arterial reconstruction. For example, the total number of femoral-above knee popliteal artery bypass was 102 (100), higher than 91 (89), the number of actual applications in Table 4 -2. It may have reflected the content of other procedures because the bypass procedure can be simultaneously applied with other procedures (TEA). Multiple procedures can be selected at the same time for lower limb arterial reconstruction. This is also the reason for unused.
(4) Outcomes early (one month) after treatment
Tables 5-1 to 5-8 show the outcomes early (one month) after treatment. At the time of summary count at the end of March 2018, follow-up data one month after treatment were obtained in 830 limbs (76%), including 813 limbs (76%) with ASO. Data were collected according to the severity of the local limb conditions (Rutherford classification) and treatment measures (EVT alone or surgical reconstruction with/without EVT). The mortality was 3.4% (3.3%) in the whole series, and 4.5% (4.5%) and 2.5% (2.4%) treated by EVT alone and by surgical reconstruction with/without EVT, respectively. The most common cause of death was cardiac disease, accounting for 29% (30%) of all deaths. Postoperative complications were cardiac disease in 2.1% (2.1%), cerebrovascular disease in 1.9% (2.0%), pneumonia in 2.3% (2.2%), and wound complication in 5.4% (5.0%). Complications at the puncture site were noted in 1.8% (1.8%) of the limbs treated by EVT.
The median ABI and SPP of the measured limbs, immediately after treatment and one month after treatment, were 0.88 (0.88) and 0.92 (0.92) and 38.5 (39) mmHg and 43 (43) mmHg, respectively. Stenosis, occlusion, infection, or other trouble occurred after revascularization by EVT in 9.8% (9.6%) and by surgical reconstruction in 6.8% (6.3%). Secondary major amputation rate was 6.2% (6.3%) in EVT and 3.8% (3.9%) in surgical reconstruction. When ambulatory function at discharge was compared to that before surgery, the rate of patients with ambulatory changed from 58% (58%) to 54% (54%), ambulatory/homebound from 20% (20%) to 19% (19%), and non-ambulatory from 22% (22%) to 26% (27%).
The problems, comments, and considerations on these spreadsheets are described below. The number of bypass graft/EVT condition, clinical symptoms of the limb, ischemic wound, and ambulatory function at discharge did not match ( Table 5-5 ). The total number of ambulatory function at discharge was 830 (813), which was equal to the number of life prognoses (Table 5-1) , indicating no unused. The number of bypass graft/EVT condition was not equal to the number of ambulatory function at discharge because the objectives of bypass graft/EVT condition were limbs of survivors with arterial reconstruction and because more than one condition could be selected. The number of clinical symptoms of the limb and ischemic wound were not identical. They must be identical because their objectives were survivor without major amputations. This is speculated to be due to the presence of unused. Table 5 -3, the registration of complication at puncture site in non-reconstruction and surgical reconstruction seems to be odd. The registration of complication at puncture site is required in limbs where percutaneous transluminal angioplasty/stent placement was selected in the revascularization method. Since multiple treatment methods can be selected, complications at the puncture site was registered in non-reconstruction and surgical reconstruction.
The number of limbs of survivors with EVT was 322 limbs (320 limbs) (Table 5-1), which was 3 (3) limbs higher than the sum of the number in the column of minor reintervention or major reintervention in the row of limbs with EVT; 319 limbs (317 limbs) (Table 5-6). The number of limbs of survivors with surgical reconstruction was 427 limbs (415 limbs) (Table 5-1), which was 4 (4) limbs more than the sum of the number in the column of minor reintervention or major reintervention in the row of limbs with surgical reconstruction; 423 limbs (411 limbs) ( Table 5 
-6).
Since registration in minor reinterventions and in major reinterventions cannot be performed simultaneously, and the patient may die after reintervention, the sum of the number of minor interventions or major interventions must be higher than the number of survivors. However, the sum of the number of minor interventions or major interventions was lower than the number of survivors. This is speculated to be due to unused.
In addition to the above, there were some parts where the total number does not match in Tables 5-1 
Conclusions
Vascular surgeons contribution in participating facilities registered a sufficient amount of detailed data during busy clinical practice, which has been gradually clarifying the current status of CLI treatment in Japan. Data on CLI in 2016 were clarified, after those in 2013, 2014, and 2015. The JCLIMB Committee is planning to continue publishing an annual report. In 2017, the new concept, chronic limb threatening ischemia, was proposed instead of CLI. 14) In addition, a new clinical guideline, the Global Vascular Guideline, will be published instead of TASC in the near future. The JCLIMB Committee ought to revise the survey items hereafter.
Clinical studies using these data are being started in 2018. The JCLIMB Committee expects these study results will be fed back to clinical situations to help develop medical care for CLI. Facilities can participate in JCLIMB at any time by contacting the JSVS secretariat for details.
In the future, JCLIMB is designed to be extended to a system where physicians in departments other than vascular surgery will be able to register, track, and analyze CLI, aiming at establishing a nationwide CLI database in Japan.
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Additional Remarks
This Annual Report was primarily published in the Japanese Journal of Vascular Surgery Vol. 28 (2019) No. 1; however, an error in a table was detected after the publication. The errata was published in the same volume. This translation reflects that correction. Local infection involving only the skin and the subcutaneous tissue (without involvement of deeper tissues and without systemic signs as described below).
JSVS JCLIMB Committee, NCD JCLIMB Analytical Team
Exclude other causes of an inflammatory response of the skin (e.g., trauma, gout, acute Charcot neuro-osteoarthropathy, fracture, thrombosis, venous stasis) 2 Local infection (as described above) with erythema >2 cm, or involving structures deeper than skin and subcutaneous tissues (e.g., abscess, osteomyelitis, septic arthritis, fasciitis), and no systemic inflammatory response signs (as described below) Moderate 
Involving only the skin and the subcutaneous tissue (Erythema around the ulcer; 0.5-2 cm)
Involving only the skin and the subcutaneous tissue (Erythema around the ulcer; >2 cm), or involving structures deeper than skin and subcutaneous tissues (e.g., abscess, osteomyelitis, septic arthritis, fasciitis)
JSVS JCLIMB Committee, NCD JCLIMB Analytical Team 0  1  2  3  0  1  2  3  0  1  2  3  1  2  3  4   Rutherford 4 235  0  0  0  18  33  53  62  218  10  7  0  50  107  9  0   Rutherford 5  0  279  329  97  58  113  178  238  465  151  76  13  69  104  178  236   Rutherford 6  0  11  34  107  8  17  31  56  53  30  57  12  3  6  15  88   Total  235  290  363  204  84  163  262  356  736  191  140  25  122  217  202  324   b. ASO   Wound  Ischemia  Foot infection  Stage   0  1  2  3  0  1  2  3  0  1  2  3  1  2  3  4   Rutherford 4 233  0  0  0  18  33  52  62  216  10  7  0  50  106  9  0   Rutherford 5  0  273  318  97  54  113  174  233  456  146  75  11  67  102  175  230   Rutherford 6  0  11  32  106  8  17  30  54  52  30  55  12  3  6  15  85   Total  233  284  350  203  80  163  256  349  724  186  137  23  120  214 199 315 
